{
  "abstract": "Objectives Voclosporin is approved for the treatment of adults with active lupus nephritis (LN). In the Phase 3 AURORA studies, voclosporin plus mycophenolate mofetil and low-dose glucocorticoids led to significant reductions in proteinuria while maintaining a stable estimated glomerular filtration rate (eGFR) for up to 3 years of follow-up. Biologic therapies are frequently used in systemic lupus erythematosus as well as in LN, yet information on the use of voclosporin in combination with these agents is limited. Here we describe the baseline characteristics and demographics of patients enrolled in the Enlight-LN registry and detail the use of concomitant medications, specifically biologics.Methods The Enlight-LN registry enrolled patients between March 2022 and January 2025 ( NCT05337124). Enrolled patients were greater than or equal to 18 years with biopsy-confirmed LN who initiated or had already initiated treatment with commercial voclosporin prior to study consent. Patients received standard of care in accordance with usual clinical practice at each site.Results As of April 4, 2025, data were available on 229 patients. Median (range) patient age was 34.0 (18-78) years, with 36.2% of patients less than or equal to 30 years; 83.4% were female. Most patients self-identified as White (43.2%) or Black/African American (38.0%); 35.4% were Hispanic/Latino. Median (range) time since first LN diagnosis was 1.6 (0-26.2) years. The majority of patients had Class V disease (31.4%), Class IV disease (20.1%), or mixed Class IV/V disease (15.7%). Median (range) eGFR was 89.3 (6-170) mL/min/1.73 m2; 10.4% of patients had baseline eGFR <45 mL/min/1.73 m2. Median (range) urine protein creatinine ratio (UPCR) was 2.3 (0.1-16.8) g/g; 38.2% of patients had baseline UPCR greater than or equal to 3 g/g.There were 83 (36.2%) patients on voclosporin who concomitantly received treatment with a biologic including belimumab (28.4%), rituximab (4.8%), anifrolumab (3.9%) and obinutuzumab (1.3%).Conclusions This initial analysis portrays the use of concomitant immunosuppressive biologics in LN patients treated with voclosporin. This is notable given the unique and possibly synergistic effects of these agents on the immune system. Additional analysis of the registry data will provide further clinical and mechanistic insights into the use of these multi-targeted therapeutic approaches.",
  "authors": [
    {
      "affiliations": [
        "Aurinia Pharmaceuticals Inc., Rockville, USA"
      ],
      "name": "Vanessa Birardi"
    },
    {
      "affiliations": [
        "University of California Los Angeles, Los Angeles, USA"
      ],
      "name": "Mohammad Kamgar"
    },
    {
      "affiliations": [
        "Columbia University, New York, USA"
      ],
      "name": "Laura Geraldino-Pardilla"
    },
    {
      "affiliations": [
        "University of Southern California, Los Angeles, USA"
      ],
      "name": "Leanna M Wise"
    },
    {
      "affiliations": [
        "University of California Los Angeles, Los Angeles, USA"
      ],
      "name": "Niloofar Nobakht"
    },
    {
      "affiliations": [
        "Aurinia Pharmaceuticals Inc., Rockville, USA"
      ],
      "name": "Barbara Mcintosh"
    },
    {
      "affiliations": [
        "Aurinia Pharmaceuticals Inc., Rockville, USA"
      ],
      "name": "Ernie Yap"
    },
    {
      "affiliations": [
        "Aurinia Pharmaceuticals Inc., Rockville, USA"
      ],
      "name": "Ronald Flauto"
    }
  ],
  "title": "PO:09:248 Real-world data on voclosporin for the treatment of lupus nephritis including use of concomitant biologic therapies: an analysis of the Enlight-LN registry",
  "uid": "d3495881-0e0c-509d-8886-a5764dd8e367"
}